**Supplemental data**

e1. Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies. J Neuroinflammation. Journal of Neuroinflammation; 2017;14:1–10.

e2. Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22:530–546.

e3. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI, Kordula T. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem. 2011;286:29893–29903.

e4. Hyvärinen T, Hagman S, Ristola M, et al. Co-stimulation with IL-1β and TNF-α induces an inflammatory reactive astrocyte phenotype with neurosupportive characteristics in a human pluripotent stem cell model system. Sci Rep. 2019;9:1–15.

e5. Ku BM, Lee YK, Ryu J, et al. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer. 2011;128:1316–1326.

e6. Wurm J, Behringer SP, Ravi VM, et al. Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma. Cancers (Basel) [online serial]. MDPI; 2019;11:1437. Accessed at: https://pubmed.ncbi.nlm.nih.gov/31561550.

e7. Li L, Tian E, Chen X, et al. GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease. Cell Stem Cell. 2018;23:239-251.e6.

e8. Starossom SC, Campo Garcia J, Woelfle T, et al. Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. Nat Commun. 2019;10.

e9. Matute-Blanch C, Calvo-Barreiro L, Carballo-Carbajal I, et al. Chitinase 3-like 1 is neurotoxic in primary cultured neurons. Sci Rep. 2020;10:1–6.

e10. Im JH, Yeo IJ, Park PH, et al. Deletion of Chitinase-3-like 1 accelerates stroke development through enhancement of Neuroinflammation by STAT6-dependent M2 microglial inactivation in Chitinase-3-like 1 knockout mice. Exp Neurol [online serial]. Elsevier; 2020;323:113082. Accessed at: https://doi.org/10.1016/j.expneurol.2019.113082.

e11. Wiley CA, Bonneh-Barkay D, Dixon CE, et al. Role for mammalian chitinase 3-like protein 1 in traumatic brain injury. Neuropathology. Australia; 2015;35:95–106.

e12. Bonneh-Barkay D, Wang G, Laframboise WA, Wiley CA, Bissel SJ. Exacerbation of experimental autoimmune encephalomyelitis in the absence of breast regression protein 39/chitinase 3-like 1. J Neuropathol Exp Neurol [online serial]. 2012;71:948–958. Accessed at: https://pubmed.ncbi.nlm.nih.gov/23041842.

e13. Cantó E, Espejo C, Costa C, Montalban X, Comabella M. Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. Clin Immunol [online serial]. Elsevier B.V.; 2015;160:133–141. Accessed at: http://dx.doi.org/10.1016/j.clim.2015.06.004.

e14. Choi JY, Yeo IJ, Kim KC, et al. K284-6111 prevents the amyloid beta-induced neuroinflammation and impairment of recognition memory through inhibition of NF-ΚB-mediated CHI3L1 expression. J Neuroinflammation. Journal of Neuroinflammation; 2018;15:1–13.

e15. Hinsinger G, Galéotti N, Nabholz N, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler J [online serial]. SAGE Publications Ltd STM; 2015;21:1251–1261. Accessed at: https://doi.org/10.1177/1352458514561906.

e16. Møllgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. Eur J Neurol. 2016;23:898–905.

e17. Sanfilippo C, Nunnari G, Calcagno A, et al. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). Virus Res [online serial]. Elsevier B.V.; 2017;227:220–230. Accessed at: http://dx.doi.org/10.1016/j.virusres.2016.10.012.

e18. Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR. CSF chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:1215–1220.

e19. Sanfilippo C, Longo A, Lazzara F, et al. CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients. Mol Cell Neurosci. 2017;85:162–169.

e20. Wagner CA, Roqué PJ, Goverman JM. Pathogenic T cell cytokines in multiple sclerosis. J Exp Med. 2020;217.

e21. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med [online serial]. Elsevier; Epub 2020 Jul 31. Accessed at: https://doi.org/10.1016/j.amjmed.2020.05.049.

e22. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113–126.

e23. Canto E, Tintore M, Villar LM, et al. Chitinase 3-like 1: Prognostic biomarker in clinically isolated syndromes. Brain. 2015;138:918–931.

e24. Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. England; 2015;21:1761–1770.

e25. Martínez MAM, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler J [online serial]. SAGE Publications Ltd STM; 2015;21:550–561. Accessed at: https://doi.org/10.1177/1352458514549397.

e26. Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmeström C. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol. Netherlands; 2016;292:52–57.

e27. Cantó E, Reverter F, Morcillo-Suárez C, et al. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler. England; 2012;18:983–990.

e28. Gil-Perotin S, Castillo-Villalba J, Cubas-Nuñez L, et al. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front Neurol. 2019;10:1008.

e29. Håkansson I, Tisell A, Cassel P, et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation. 2018;15:209.

e30. Olsson T, Stoop MP, Khademi M, et al. Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients. J Proteome Res. 2013;12:1101–1107.

e31. Novakova L, Axelsson M, Khademi M, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. England; 2017;23:62–71.

e32. Matute-Blanch C, Río J, Villar LM, et al. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. J Neuroimmunol [online serial]. Elsevier B.V.; 2017;303:62–65. Accessed at: http://dx.doi.org/10.1016/j.jneuroim.2016.12.006.

e33. Sellebjerg F, Börnsen L, Ammitzbøll C, et al. Defining active progressive multiple sclerosis. Mult Scler [online serial]. Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; 2017;23:1727–1735. Accessed at: http://europepmc.org/abstract/MED/28831853.

e34. Oldoni E, Smets I, Mallants K, et al. CHIT1 at Diagnosis Reflects Long-Term Multiple Sclerosis Disease Activity. Ann Neurol. 2020;87:633–645.

e35. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. United States; 2010;362:329–344.

e36. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging [online serial]. 2000;21:383–421. Accessed at: https://pubmed.ncbi.nlm.nih.gov/10858586.

e37. Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68:903–912.

e38. Janelidze S, Hertze J, Zetterberg H, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3:12–20.

e39. Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867–e877.

e40. Alcolea D, Vilaplana E, Pegueroles J, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. Neurobiol Aging. United States; 2015;36:2018–2023.

e41. Baldacci F, Toschi N, Lista S, et al. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer’s disease. Alzheimers Dement. United States; 2017;13:993–1003.

e42. Kester MI, Teunissen CE, Sutphen C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7:59.

e43. Alcolea D, Martínez-Lage P, Sánchez-Juan P, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. United States; 2015;85:626–633.

e44. Teunissen CE, Elias N, Koel-Simmelink MJA, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer’s Dement (Amsterdam, Netherlands). 2016;2:86–94.

e45. Wennström M, Surova Y, Hall S, et al. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies. PLoS One. 2015;10:e0135458.

e46. Rosén C, Andersson C-H, Andreasson U, et al. Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer’s Disease. Dement Geriatr Cogn Dis Extra. 2014;4:297–304.

e47. Watabe-Rudolph M, Song Z, Lausser L, et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology. United States; 2012;78:569–577.

e48. Mattsson N, Tabatabaei S, Johansson P, et al. Cerebrospinal fluid microglial markers in Alzheimer’s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med. United States; 2011;13:151–159.

e49. Llorens F, Thüne K, Tahir W, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12:83.

e50. Moreno-Rodriguez M, Perez SE, Nadeem M, Malek-Ahmadi M, Mufson EJ. Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer’s disease. J Neuroinflammation. Journal of Neuroinflammation; 2020;17:1–15.

e51. Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim [online serial]. 2017;3:17071. Accessed at: https://doi.org/10.1038/nrdp.2017.71.

e52. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. England; 2011;10:253–263.

e53. Thompson AG, Gray E, Thézénas M-L, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018;83.

e54. Varghese AM, Sharma A, Mishra P, et al. Chitotriosidase - A putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics. 2013;10:1–9.

e55. Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. Epub 2020.

e56. Gille B, De Schaepdryver M, Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90:1338–1346.

e57. Vu L, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry. Epub 2020.:350–358.

e58. Oeckl P, Weydt P, Steinacker P, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90:4–10.

e59. Andrés-Benito P, Domínguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging (Albany NY) [online serial]. Impact Journals; 2018;10:2367–2382. Accessed at: https://pubmed.ncbi.nlm.nih.gov/30215603.

e60. Illán-Gala I, Alcolea D, Montal V, et al. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:E1619–E1628.

e61. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–322.

e62. Campbell BC V, De Silva DA, Macleod MR, et al. Ischaemic stroke. Nat Rev Dis Prim [online serial]. 2019;5:70. Accessed at: https://doi.org/10.1038/s41572-019-0118-8.

e63. Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. United States; 1999;19:687–694.

e64. Bustamante A, Dominguez C, Rodriguez-Sureda V, et al. Prognostic value of plasma chitotriosidase activity in acute stroke patients. Int J Stroke. 2014;9:910–916.

e65. Sotgiu S, Barone R, Zanda B, et al. Chitotriosidase in patients with acute ischemic stroke. Eur Neurol. Switzerland; 2005;54:149–153.

e66. Park HY, Jun C-D, Jeon S-J, et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One. United States; 2012;7:e51722.

e67. Chen X-L, Li Q, Huang W-S, et al. Serum YKL-40, a prognostic marker in patients with large-artery atherosclerotic stroke. Acta Neurol Scand. Denmark; 2017;136:97–102.

e68. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol. 2010;68:672–680.

e69. Rathcke CN, Thomsen SB, Linneberg A, Vestergaard H. Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS One. 2012;7.

e70. Ridker PM, Chasman DI, Rose L, Loscalzo J, Elias JA. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3l1), and incident cardiovascular events. J Am Heart Assoc. 2014;3:1–17.

e71. Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke. 2015;46:329–335.

e72. Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013. Morb Mortal Wkly report Surveill Summ (Washington, DC 2002). 2017;66:1–16.

e73. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury. Netherlands; 2007;38:1392–1400.

e74. Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift. Neuron [online serial]. Elsevier Inc.; 2017;95:1246–1265. Accessed at: https://doi.org/10.1016/j.neuron.2017.07.010.

e75. Bonneh-Barkay D, Zagadailov P, Zou H, et al. YKL-40 expression in traumatic brain injury: An initial analysis. J Neurotrauma. 2010;27:1215–1223.

e76. Carabias CS, Gomez PA, Panero I, et al. Chitinase-3-Like Protein 1, Serum Amyloid A1, C-Reactive Protein, and Procalcitonin Are Promising Biomarkers for Intracranial Severity Assessment of Traumatic Brain Injury: Relationship with Glasgow Coma Scale and Computed Tomography Volumetry. World Neurosurg. United States; 2020;134:e120–e143.

e77. Shahim P, Tegner Y, Marklund N, et al. Astroglial activation and altered amyloid metabolism in human repetitive concussion. Neurology. 2017;88:1400–1407.

e78. Harish G, Mahadevan A, Pruthi N, et al. Characterization of traumatic brain injury in human brains reveals distinct cellular and molecular changes in contusion and pericontusion. J Neurochem. 2015;134:156–172.

e79. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis [online serial]. Elsevier; 2020;20:e2–e10. Accessed at: https://doi.org/10.1016/S1473-3099(19)30615-2.

e80. Abu-Rumeileh S, Steinacker P, Polischi B, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer’s Res Ther. Alzheimer’s Research & Therapy; 2019;12:1–15.

e81. Villar-Piqué A, Schmitz M, Hermann P, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. Journal of Neuroinflammation; 2019;16:1–5.

e82. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Prim. England; 2017;3:17013.

e83. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64:110–122.

e84. Parillaud VR, Lornet G, Monnet Y, et al. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. J Neuroinflammation [online serial]. 2017;14:60. Accessed at: https://doi.org/10.1186/s12974-017-0830-9.

e85. Hall S, Surova Y, Öhrfelt A, Blennow K, Zetterberg H, Hansson O. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Mov Disord. 2016;31:898–905.

e86. Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H. The glial marker YKL-40 is decreased in synucleinopathies. Mov Disord. United States; 2013;28:1882–1885.

e87. Smail RC, Brew BJ. HIV-associated neurocognitive disorder. Handb Clin Neurol. Netherlands; 2018;152:75–97.

e88. Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res. Netherlands; 2003;1:463–473.

e89. Hermansson L, Yilmaz A, Axelsson M, et al. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. J Neuroinflammation. 2019;16:16.

 e90. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. Germany; 2000;250:274–285.

e91. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. United States; 2000;47:210–220.

e92. Zhao X, Tang R, Gao B, et al. Functional variants in the promoter region of chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet. 2007;80:12–18.

e93. Horváth S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry [online serial]. Elsevier; 2014;75:316–323. Accessed at: http://dx.doi.org/10.1016/j.biopsych.2013.06.010.

e94. Orhan F, Schwieler L, Fatouros-Bergman H, et al. Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis. Acta Psychiatr Scand. 2018;138:432–440.

e95. Chung C, Tallerico T, Seeman P. Schizophrenia hippocampus has elevated expression of chondrex glycoprotein gene. Synapse. 2003;50:29–34.

e96. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular Evidence for Increased Expression of Genes Related to Immune and Chaperone Function in the Prefrontal Cortex in Schizophrenia. Biol Psychiatry. 2007;62:711–721.

e97. Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Prim [online serial]. 2018;4:18008. Accessed at: https://doi.org/10.1038/nrdp.2018.8.

e98. Khansari PS, Sperlagh B. Inflammation in neurological and psychiatric diseases. Inflammopharmacology. 2012;20:103–107.

e99. Jakobsson J, Bjerke M, Sahebi S, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci. 2015;40:250–258.

e100. Rolstad S, Jakobsson J, Sellgren C, et al. CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. Eur Neuropsychopharmacol [online serial]. Elsevier; 2015;25:1091–1098. Accessed at: http://dx.doi.org/10.1016/j.euroneuro.2015.04.023.

e101. Isgren A, Sellgren C, Ekman CJ, et al. Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain Behav Immun [online serial]. Elsevier Inc.; 2017;65:195–201. Accessed at: http://dx.doi.org/10.1016/j.bbi.2017.05.002.